Salmon Omega-3: EPA and DHA

Of the dozens of fatty acids in human nutrition, only two are essential (alpha-linolenic acid and linoleic acid) and only two of the long-chain derivatives are unambiguously rate-limiting for health: eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). These long-chain omega-3s are the substrates for resolvin and protectin biosynthesis (the resolution-of-inflammation lipid mediators discovered by Charles Serhan at Harvard), the structural fatty acids of neuronal membranes and the retina, and the only fatty acids whose dietary intake reliably reduces cardiovascular mortality in randomized trials. Salmon is the most widely available whole-food source: a 3.5 oz serving of wild sockeye delivers approximately 1,200 mg of combined EPA + DHA, two of which per week meets the American Heart Association recommendation for the general adult population.

Table of Contents

  1. Why Marine Omega-3s Are Different from ALA
  2. The ALA-to-EPA-to-DHA Elongation Pathway (and Why It's Inefficient)
  3. EPA, Resolvins, and the Resolution of Inflammation
  4. DHA in the Brain and Retina
  5. Cardiovascular Trials: GISSI, JELIS, REDUCE-IT
  6. Triglyceride Reduction and Lipid Profile
  7. Dosing: AHA Recommendation and Therapeutic Doses
  8. Pregnancy, Lactation, and Infant Neurodevelopment
  9. Mental Health Applications (Depression, ADHD)
  10. Fish Oil Capsules vs Whole Fish
  11. Cautions and Drug Interactions
  12. Key Research Papers
  13. Connections

Why Marine Omega-3s Are Different from ALA

Public confusion persists because "omega-3" is a chemical-family label, not a single nutrient. The omega-3 family contains three nutritionally relevant fatty acids:

The clinical distinction is fundamental: the cardiovascular, neurodevelopmental, anti-inflammatory, and triglyceride-lowering effects documented in randomized trials are produced by EPA and DHA. Trials of ALA alone (without concurrent EPA + DHA) have not consistently reproduced these effects. The reason is the elongation-pathway inefficiency discussed in the next section.

This matters because vegan and vegetarian dietary advice often substitutes flax or chia for fish, with the implicit assumption that "omega-3 is omega-3." For most adults this is incorrect — flaxseed oil provides ALA but very little of it is converted to the long-chain EPA and DHA that the body actually needs. The vegan exception is algae-derived DHA and EPA supplements, which deliver the long-chain forms directly without requiring fish.

Back to Table of Contents

The ALA-to-EPA-to-DHA Elongation Pathway (and Why It's Inefficient)

The human body can in principle convert dietary ALA to EPA and then to DHA through a series of enzymatic desaturations and elongations:

ALA (18:3) → Stearidonic Acid (18:4) → Eicosatetraenoic Acid (20:4) → EPA (20:5) → DPA (22:5) → Tetracosapentaenoic (24:5) → Tetracosahexaenoic (24:6) → DHA (22:6)

The pathway requires the enzymes delta-6 desaturase (FADS2), elongase, delta-5 desaturase (FADS1), and beta-oxidation. The same enzymes also process the parallel omega-6 pathway (linoleic acid → arachidonic acid), which creates competitive inhibition.

Conversion efficiency in healthy adults:

The clinical implication is that a tablespoon of flaxseed oil (containing roughly 7,000 mg ALA) supplies only approximately 100-700 mg of EPA-equivalent and as little as 30-200 mg of DHA-equivalent through the conversion pathway. By contrast, a 3.5 oz serving of wild sockeye salmon supplies approximately 600 mg EPA and 600 mg DHA directly. The whole-fish source bypasses the rate-limiting conversion entirely.

This is a major reason that pre-formed EPA and DHA (from fatty fish, fish oil, or algae oil) are functionally non-substitutable with ALA from plant sources for individuals with cardiovascular risk, depression, ADHD, or pregnancy demand on DHA stores. Plant sources contribute, but they are inefficient relative to direct marine intake.

Back to Table of Contents

EPA, Resolvins, and the Resolution of Inflammation

The traditional model of inflammation focused on initiation (TNF-alpha, IL-6, prostaglandins driving the inflammatory cascade) and resolution as a passive process — inflammation ended when the initiating signal stopped. Charles Serhan's laboratory at Harvard upended this model in the 2000s by identifying a class of endogenous lipid mediators, the specialized pro-resolving mediators (SPMs), that actively terminate inflammation by signaling neutrophil apoptosis, macrophage efferocytosis, and tissue regeneration.

The SPM families and their substrates:

The SPMs explain why omega-3 supplementation produces broad anti-inflammatory effects that the simple "EPA competes with arachidonic acid for COX/LOX enzymes" model could not fully account for. EPA and DHA are not just precursors that reduce omega-6-derived inflammation; they are precursors for an entire parallel resolution-of-inflammation signaling system.

The clinical implications are still being mapped. SPM analogs are in clinical trials for diseases of failed inflammation resolution (chronic periodontitis, dry eye disease, persistent post-surgical pain). For the average adult, the takeaway is that consistent dietary EPA and DHA intake provides the substrate for ongoing endogenous SPM biosynthesis, a baseline anti-inflammatory tone that the omega-3-deficient Western diet lacks.

Back to Table of Contents

DHA in the Brain and Retina

DHA is the most abundant omega-3 fatty acid in the brain, comprising approximately 30% of total gray-matter phospholipid by mass. It is concentrated particularly in synaptic membranes (the highly dynamic membranes where neurotransmission occurs) and in retinal rod outer-segment discs (where it can comprise 50% or more of phospholipid acyl chains).

Why DHA in these locations? The molecule's 22-carbon chain with 6 cis double bonds creates an unusually fluid, conformationally dynamic structure that supports:

DHA deficiency during the critical brain growth period (third trimester of pregnancy through the first 2 years of life) is associated with reduced infant visual acuity scores, reduced cognitive scores in preschool age, and increased behavioral problems. The DOMINO trial and several other randomized trials of maternal DHA supplementation have shown modest but consistent improvements in infant neurodevelopmental outcomes, with the largest effects in mothers who started supplementation with the lowest baseline DHA status.

For adults, the brain-DHA story extends to depression (lower DHA levels in depressed populations), age-related cognitive decline (Framingham and other cohorts show fish consumption associated with reduced dementia incidence), and macular degeneration (DHA is one of the substrates the AREDS2 formulation indirectly supports). For more on the structural role of DHA in the eye, see our Vitamin A Vision page.

Back to Table of Contents

Cardiovascular Trials: GISSI, JELIS, REDUCE-IT

The cardiovascular evidence for marine omega-3 intake has progressed through three generations of landmark trials.

GISSI-Prevenzione (1999, The Lancet): 11,324 post-myocardial-infarction Italian patients randomized to 1 g/day omega-3 (EPA + DHA, approximately 850 mg combined) or placebo. After 3.5 years, the omega-3 group had a 20% reduction in all-cause mortality, 30% reduction in cardiovascular mortality, and 45% reduction in sudden cardiac death. The benefit was driven primarily by reduction in arrhythmic death, plausibly through the stabilizing effect of EPA and DHA on cardiomyocyte ion channels.

JELIS (2007, The Lancet): 18,645 Japanese hypercholesterolemic patients on statin therapy were randomized to add 1.8 g/day EPA (no DHA) or placebo. The EPA arm had a 19% reduction in major coronary events. The trial was important because it was conducted in a Japanese population with already-high dietary fish intake at baseline, and yet additional EPA still produced benefit.

REDUCE-IT (2019, NEJM): 8,179 statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes plus risk factors were randomized to 4 g/day icosapent ethyl (a purified EPA ethyl ester, brand name Vascepa) or mineral-oil placebo. The EPA arm had a 25% reduction in major adverse cardiovascular events, leading to FDA approval of icosapent ethyl as adjunct therapy for elevated triglycerides with statin treatment.

Notably, the parallel trial of similar design using a mixed EPA/DHA preparation (STRENGTH trial, 2020) did NOT show benefit. This has driven ongoing scientific debate about whether the cardiovascular benefit is specifically attributable to EPA or to a particular EPA:DHA ratio. The clinical consensus remains that whole-food intake of fatty fish providing both EPA and DHA is the recommended population intervention, while purified EPA at high dose has the strongest randomized-trial evidence for high-risk secondary prevention.

For the underlying cardiovascular biology, see our Cardiology page.

Back to Table of Contents

Triglyceride Reduction and Lipid Profile

Marine omega-3 intake at therapeutic doses produces a consistent, dose-dependent reduction in serum triglycerides. The mechanism involves:

At pharmacologic doses (3-4 g/day combined EPA + DHA), serum triglycerides typically fall by 20-50% from baseline, an effect that scales with baseline triglyceride level. This is meaningful for patients with hypertriglyceridemia (TG >500 mg/dL), where omega-3 prescription products (Lovaza, Vascepa, Omtryg) are FDA-approved for triglyceride reduction.

The effect on LDL cholesterol is variable and less pronounced. EPA-only preparations (icosapent ethyl) tend to be LDL-neutral. Mixed EPA + DHA preparations sometimes produce a small LDL increase, particularly in patients with severely elevated baseline TG. HDL typically rises modestly (3-5%).

The whole-food salmon translation: 2-3 servings per week supplies approximately 3-4 g/week of combined EPA + DHA, which is enough to produce meaningful improvements in inflammatory markers and modest improvements in triglycerides for moderately elevated baseline values. For patients with TG >500 mg/dL requiring substantial reduction, prescription omega-3 at 4 g/day is generally needed in addition to dietary fish.

Back to Table of Contents

Dosing: AHA Recommendation and Therapeutic Doses

The American Heart Association recommends:

European Food Safety Authority recommendations are slightly higher (250-500 mg/day EPA + DHA for general adult intake), and several other professional societies recommend similar ranges.

Practical translation to salmon servings:

For non-fish-eaters, the equivalent dose can be obtained from approximately 1-2 standard fish oil capsules (typically 300-500 mg combined EPA + DHA each) or 1-2 algae oil capsules per day.

Back to Table of Contents

Pregnancy, Lactation, and Infant Neurodevelopment

The third trimester of pregnancy is the period of fastest fetal brain growth, and DHA accumulation in the fetal brain accelerates dramatically during this window. The fetal supply depends entirely on maternal DHA status and transplacental transfer. After birth, infant DHA continues to come from breast milk (or formula DHA fortification) for the entire first year, supporting continued brain development.

The clinical evidence:

Practical recommendations for pregnancy: 2-3 servings per week of low-mercury fatty fish (salmon is a top choice along with sardines, herring, and anchovies). Pregnant women should avoid the high-mercury apex predators (king mackerel, marlin, swordfish, shark, bigeye tuna, tilefish from the Gulf of Mexico). Salmon is on the FDA-EPA "Best Choices" list for pregnancy.

Back to Table of Contents

Mental Health Applications (Depression, ADHD)

Lower serum and red-cell membrane EPA and DHA levels have been observed in populations with major depressive disorder, postpartum depression, bipolar disorder, ADHD, and schizophrenia across multiple cross-sectional and case-control studies. The mechanism is plausible (DHA in synaptic membranes affects neurotransmission; resolvins affect neuroinflammation now recognized as a depression contributor), but the randomized-trial evidence for therapeutic supplementation is mixed.

For mental health applications, the dose tends to be higher than the general cardiovascular dose — typically 2-4 g/day of combined EPA + DHA with EPA predominance, taken for at least 8-12 weeks. Whole-food salmon contributes meaningfully but most mental-health trial protocols use supplementation in addition to dietary intake.

Back to Table of Contents

Fish Oil Capsules vs Whole Fish

For a given delivered dose of EPA and DHA, are fish oil capsules equivalent to whole salmon? Several considerations matter:

The pragmatic recommendation: whole-food salmon (and other oily fish) for 2-3 meals per week is the gold standard. Fish oil supplementation is useful for individuals who cannot or do not eat fish, for therapeutic doses beyond what can be obtained from fish alone (e.g. 3-4 g/day for major depression or REDUCE-IT-style secondary prevention), and as a convenient option for travel and other dietary disruptions.

For pure vegan / vegetarian alternatives, algae-derived DHA (and increasingly EPA) supplements are now widely available and provide the same long-chain omega-3s that fish would otherwise supply.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. GISSI-Prevenzione Investigators (1999). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet. — PubMed
  2. Yokoyama M et al. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). The Lancet. — PubMed
  3. Bhatt DL et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM. — PubMed
  4. Serhan CN, Chiang N, Van Dyke TE (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews Immunology. — PubMed
  5. Burdge GC, Calder PC (2005). Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reproduction Nutrition Development. — PubMed
  6. Calder PC (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. — PubMed
  7. SanGiovanni JP, Chew EY (2005). The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Progress in Retinal and Eye Research. — PubMed
  8. Makrides M et al. (2010). Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children (DOMInO trial). JAMA. — PubMed
  9. Mozaffarian D, Wu JH (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. JACC. — PubMed
  10. Mocking RJ et al. (2016). Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Translational Psychiatry. — PubMed
  11. Bloch MH, Qawasmi A (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology. JAACAP. — PubMed
  12. Nicholls SJ et al. (2020). Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents